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Statement of clinical relevance 
The prospective randomized DIRECTOR trial assessed the efficacy and tolerability of 
two different regimens of rechallenge with intensified temozolomide (TMZ) at first 
progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ). 
Efficacy was similar in both arms, but depended strongly on MGMT promoter 
methylation status. TMZ rechallenge should no longer be considered for patients with 
tumors lacking MGMT promoter methylation, but is an appropriate option for patients 
with glioblastoma harboring MGMT promoter methylation at first relapse. 
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Abstract 
 
Purpose 
Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after 
temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective 
and single-arm prospective studies, applying TMZ continuously or using 7/14 or 
21/28 days schedules. The DIRECTOR trial sought to show superiority of the 7/14 
regimen. 
Patients & Methods 
Patients with glioblastoma at first progression after TMZ/RT→TMZ and at least 2 
maintenance TMZ cycles were randomized to Arm A (one week on (120 mg/m2 per 
day) / one week off) or Arm B (three weeks on (80 mg/m2 per day) / one week off). 
The primary end point was median time to treatment failure (TTF) defined as 
progression, premature TMZ discontinuation for toxicity, or death from any cause. O6-
methylguanine DNA methyltransferase (MGMT) promoter methylation was 
prospectively assessed by methylation-specific PCR. 
Results 
Because of withdrawal of support, the trial was prematurely closed to accrual after 
105 patients. There was a similar outcome in both arms for median TTF (A: 1.8 
months [95% CI 1.8-3.2] versus B: 2.0 months [95% CI 1.8-3.5]) and overall survival 
(OS) (A: 9.8 months [95% CI 6.7-13.0] versus B: 10.6 months [95% CI 8.1-11.6]). 
Median TTF in patients with MGMT-methylated tumors was 3.2 months [95% CI 1.8-
7.4] versus 1.8 months [95% CI 1.8-2] in MGMT-unmethylated glioblastoma. 
Progression-free survival rates at six months (PFS-6) were 39.7% with versus 6.9% 
without MGMT promoter methylation. 
Conclusions 
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TMZ rechallenge is a treatment option for MGMT promoter-methylated recurrent 
glioblastoma. Alternative strategies need to be considered for patients with 
progressive glioblastoma without MGMT promoter methylation. 
 
 
Introduction 
 
The standard of care for newly diagnosed glioblastoma, with an incidence of more 
than 3/100,000 the most common primary malignant brain tumor, includes resection 
or biopsy as feasible, involved field radiotherapy, and concomitant and adjuvant 
temozolomide (TMZ/RT→TMZ) (1). While anti-angiogenic agents such as the 
antibody to vascular endothelial growth factor, bevacizumab, or the integrin inhibitor 
cilengitide failed to prolong overall survival (2-4), the novel approach of tumor-
treating fields provided a survival advantage and may be incorporated into the future 
first-line treatment (5). 
Standards of care at progression are less well defined (6): Depending on approval 
status, individual patient and tumor factors, and local preference, the most commonly 
used systemic therapeutic approaches include nitrosoureas such as lomustine 
(CCNU) which has become the standard of care in randomized clinical trials for 
recurrent glioblastoma (7, 8), temozolomide rechallenge using various regimens (9-
12), and bevacizumab (13, 14). The need for prospective assessment of TMZ 
rechallenge after systematic recognition of pseudoprogression as a potential 
confounder of second-line treatments (15, 16) and the controversy regarding the 
optimal dosing of TMZ for patients with recurrent glioblastoma after failure of first-line 
TMZ/RT→TMZ led to the design of the DIRECTOR (Dose-Intensified Rechallenge 
with Temozolomide, One Week on One Week Off versus Three Weeks on One Week 
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Off in Patients with Progressive or Recurrent Glioblastoma) trial, which sought to 
explore the activity of two widely used regimens of dose-intense TMZ for recurrent 
glioblastoma, one week on / one week off (7/14) (9) versus three weeks on / one 
week off (10). 
 
 
Patients and Methods 
 
Study design 
DIRECTOR (NCT 00941460) was designed as a prospective, open-label, 
randomized, 2-arm trial of two competing TMZ dosing regimens for patients with 
glioblastoma at first relapse or progression. The primary objective was to show the 
superiority of Arm A (one week on / one week off) over Arm B (three weeks on / one 
week off), the primary endpoint being time to treatment failure (TTF). Major inclusion 
criteria were: progressive or recurrent glioblastoma documented by MRI no earlier 
than 180 days after first surgery for glioblastoma and no earlier than 90 days after 
completion of radiotherapy (patients with progression outside the radiation field were 
also not allowed to be entered into the trial unless these time frames were 
respected); histological diagnosis of glioblastoma; tissue available for the 
determination of O6-methylguanine DNA methyltransferase (MGMT) promoter 
methylation in the primary or in the recurrent tumor; prior treatment with TMZ/RT and 
at least two cycles of maintenance TMZ (5/28); informed consent; age 18-80 years; 
Karnofsky performance score > 50%; absolute neutrophil counts > 1,500/µl; platelet 
counts > 100,000/µl; hemoglobin > 10 g/dl; serum creatinin < 1.5-fold upper normal 
range; ASAT or ALAT < 3-fold upper normal range unless attributed to 
anticonvulsants; alkaline phosphatase < 3-fold upper normal range; women with 
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childbearing potential must have a negative serum pregnancy test ≤14 days prior to 
study enrollment. Obligatory MGMT testing of the recurrent tumor as opposed to the 
primary tumor tissue was initially required, but no longer requested when it became 
clear that the result of the MGMT status determination rarely changes in the course 
of disease (17). All patients gave written informed consent, and the study was 
approved by the local ethical committees and competent authorities. The trial was 
prematurely closed for withdrawal of support after the merger of Schering Plough 
(Kenilworth, NJ) with Merck, Sharp & Dohme (Whitehouse Station, NJ). Databank 
closure was on June 30, 2013. 
 
Central pathology review, DNA extraction and MGMT promoter methylation analysis 
All tissue samples from primary or recurrent tumor were confirmed by central 
pathology review (G.R.) to represent glioblastoma according to the World Health 
Organisation (WHO) classification of tumors of the central nervous system (18). 
Tumor DNA was extracted from formalin-fixed and paraffin-embedded tissue 
samples using the Qiagen blood and tissue DNA extraction kit (Qiagen, Hilden, 
Germany). Each tumor sample used for DNA extraction was histologically verified to 
contain vital glioblastoma tissue with an estimated tumor cell content > 80%. The 
MGMT promoter methylation status was determined by methylation-specific PCR 
(MSP) and evaluated as reported (19). This MSP assays had been used in several 
previous studies (20-22) and was proven to show high concordance with results 
obtained by the MSP assay of MDxHealth S.A. (Herstal, Belgium) (22) and DNA 
pyrosequencing (17). 
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Study Treatment 
Patients were allocated either to the one week on / one week off regimen (7/14, Arm 
A) or to the three weeks on / one week off regimen (21/28, Arm B) of dose-intensified 
TMZ using a treatment allocation algorithm (23) with a probability of a minimizing 
allocation set at 0.9. Arm A patients were treated at an initial dose of 120 mg/m2 
unless there had been grade III or IV myelotoxicity with conventional TMZ (5/28) 
previously. These patients were started at 90 mg/m2. TMZ was given orally on days 
1-7 and 15-21. Arm B patients started with an initial dose of 80 mg/m2 unless there 
had been significant myelotoxicity with conventional TMZ (5/28) previously. These 
patients started at 60 mg/m2. TMZ was given orally on days 1-21. A treatment cycle 
was defined as two completed weeks of TMZ within four weeks in Arm A and as 
three weeks of continuous TMZ within four weeks in Arm B. Dose modifications were 
foreseen according to hematological parameters as outlined in Supplementary Table 
1. 
 
Assessments and endpoints 
Patients were to be seen weekly during cycle 1 and monthly thereafter for general 
evaluation and blood tests. Toxicity was evaluated using the Common Terminology 
Criteria for Adverse Events (CTCAE v3.0). Cognitive function was assessed by Mini-
Mental State Examination (MMSE) in 4-weekly intervals. Quality of life was monitored 
by EORTC QLQ-C30 and QLQ-BN20 in 8-weekly intervals. Disease status was 
monitored by MRI in 8-weekly intervals and assessed using Macdonald criteria as 
prespecified in the protocol (24). The primary endpoint, TTF, was calculated from 
randomization to any of the following: progressive disease defined by Macdonald 
criteria (24), death for any reason, or toxicity leading to discontinuation of study 
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treatment for any reason. Secondary endpoints included progression-free survival 
(PFS) calculated as the time from randomization to the first documented evidence of 
progression of disease, survival from randomization, and efficacy parameters in 
subgroups defined by MGMT status. Radiological progression was evaluated at each 
center and also centrally verified post-hoc (blindly to previous results). 
 
Statistical analyses 
The targeted sample size was 83 patients per arm, and no interim analysis was 
planned. This size would have allowed for a detection of an improvement in median 
TTF from 18.2 weeks for Arm B to 29.2 weeks for Arm A (hazard ratio 0.63) (10, 25). 
Based on these assumptions, there was approximately 80% power to detect the 
stated difference in TTF between the two treatment arms for a two-sided level of 
0.05. Treatment arms were compared using a permutation test (26) with 9999 
replicates in the Cox proportional hazard model with the same parameters as 
explanatory variables used for the treatment allocation algorithm (MGMT promoter 
methylation status, >2 months since previous TMZ treatment, age at least 50 years, 
KPS 50-60, 70-80 or 90-100) along with the variable for treatment. Since p values 
from permutation tests were sufficiently close to those based on partial likelihoods as 
routinely used in parameter estimation in the Cox model, the latter were used for all 
subgroup analyses. Secondary analyses with respect to time-to-event variables were 
done using Cox proportional hazards models when considering multiple explanatory 
variables. Log-rank or bootstrap tests to compare median times and parametric tests 
with standard error approximation were used for univariate tests, especially when 
comparing rates at fixed time points. With respect to categorical variables, we used 
Fisher’s exact test or logistic regression, and with respect to continuous variables 
linear regression models. Specifically, quality of life was analyzed using a linear 
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mixed regression model with patient as random effect. All p values, statistical tests 
and confidence intervals beyond the analysis of the primary criterion were not 
corrected for multiplicity and are to be interpreted as exploratory. 
 
 
Results 
 
Patient characteristics 
105 patients were randomized at 16 sites from 9/2009 to 6/2012. Table 1 
summarizes patient characteristics per treatment arm. Arms A and B were overall 
well balanced. More patients in Arm B had surgery for recurrent disease whereas 
more patients in Arm A had steroids at study entry. At the time of databank closure 
(30 June 2013), 87 deaths were documented, 84 were attributed to tumor 
progression, 3 documented with unknown course. No patient was still on study 
treatment. Four patients had not reached the primary endpoint of TTF (Figure 1). 
 
Safety and tolerability 
All adverse events were categorized by system organ class and graded according to 
CTCAE. There was no relevant difference between both arms regarding the 
frequency and severity of adverse events in the hematological system. Profound 
lymphopenia was the most common hematological toxicity, 19% in Arm A and 29% in 
Arm B (Supplementary Table 1). Severe infections, however, were rare. Non-
hematalogical adverse events, e.g., disorders of the gastrointestinal system, nervous 
system, metabolism, respiratory system, skin, cardiovascular system or 
musculoskeletal system occurred at similar rates in both treatment arms and were 
overall infrequent. 
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Outcome by treatment and MGMT status 
All clinical outcome parameters were comparable in Arms A and B (Figure 2, Table 
2). Median TTF was below 2 months whereas median OS from first intake of study 
drug was in the range of 10 months. The p value from the permutation test (p=0.488) 
was close enough to the p value using partial likelihood from the Cox model 
(p=0.485) to justify taking the latter one for all other analyses. There were 2 CR (4%) 
and 2 PR (4%) in Arm A and 4 CR (8%) and 4 PR (8%) in Arm B by local 
assessment (p=0.68) in response to the study treatment. The median duration of the 
6 CR was 4.5 months (95% CI 1.8-11.0). The median duration of the 6 PR was 3 
months (95% CI 1.8-13.6). TTF was diagnosed because of PD in all but three 
patients, confirming that tolerability was good. One patient developed wound 
infection at day 26, necessitating TMZ discontinuation, 2 patients died without 
documented PD. Age was not prognostic. As required per protocol MGMT status 
from primary or recurrent tumor was available for all patients. MGMT promoter 
methylation was strongly associated with superior TTF and all other outcome 
parameters (Figure 2, Table 3). The TTF difference between patients with versus 
without MGMT promoter methylation was more prominent in Arm B than in Arm A 
(Supplementary table 2). Overall survival from initial histological diagnosis of 
glioblastoma was 25.4 months (95% CI 17.8-32.3) in Arm A and 22.7 months (95% 
CI 18.5-27.2) in Arm B. This shows that patients enrolled into randomized trials for 
recurrent glioblastoma represent a selected population. 
 
Central radiology review 
Serial MRI of 85 patients were available for post-hoc central review of progression. 
All these patients had measurable disease at baseline. The time point of progression 
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was centrally confirmed in 81 patients. It was antedated 1 scan in 2 patients and not 
confirmed in 2 patients; 0 of 1 CR and 2 of 3 PR were confirmed. Insufficient scans 
were provided for the other 12 patients considered objective responders locally. 
 
Outcome by preexposure to TMZ 
We also separated the patient populations by intensity and interval of preexposure to 
TMZ. Administration of more than 6 cycles of maintenance TMZ is uncommon in 
Europe (Table 1). To this end, we compared patients with intervals below (n=40) or 
above 2 months (n=65) since their last TMZ intake as specified in the study protocol. 
Four of 6 CR and all 6 PR were noted in the latter group. Further, there was 
significantly improved outcome in patients with a longer delay since the last 
administration of TMZ, more prominent in Arm A than in Arm B and largely confined 
to patients with MGMT promoter methylation (Supplementary table 3). 
 
MMSE and quality of life 
Serial assessments of MMSE and quality of life using EORTC QLQ-C30 and QLQ-
BN20 were grouped into (i) pre-treatment, (ii) during study treatment and (iii) after 
study treatment assessments. For the latter two time intervals carrying multiple 
measures, we determined patient-wise minimum, median and maximum scores. The 
MMSE as a surrogate measure of cognitive function remained stable during 
treatment and did not exhibit a decline after the end of study treatment as long as 
data were captured (Supplementary Figure 1, Supplementary table 4). There was 
relatively little difference in quality of life assessed by QLQ-C30 and QLQ-BN20 
when compared after the first 90 days of study treatment (Supplementary table 5). 
Treatment-by-time interaction indicated that quality of life developments were 
somewhat more favorable in Arm B, with significant differences for pain 
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(Supplementary table 6). Although most scales are deteriorating over time (positive 
slope terms in either arm), the lack of major decline over time may result from the low 
number of assessments after the end of study treatment (Supplementary Table 7). 
 
Multivariate modeling of outcome 
Cox proportional hazards modeling for TTF revealed MGMT promoter methylation 
status and time interval from last TMZ exposure as independent prognostic factors 
whereas no such role was identified for age, KPS, surgery for recurrent tumor prior to 
enrolment (Table 4). Steroid administration at study entry, body surface area, body 
weight, red or white blood cell or lymphocyte counts, hemoglobin or hematocrit at 
study entry were not prognostic for TTF (data not shown). Similar results were 
obtained when Cox proportional hazards modeling was applied to PFS whereas only 
MGMT status was prognostic for survival from first study drug administration (data 
not shown). 
 
 
Discussion 
 
Standards of care in recurrent glioblastoma are not well defined. This definitive report 
of the phase II randomized DIRECTOR trial indicates that TMZ rechallenge is a valid 
treatment option for patients with recurrent glioblastoma with, but not without, MGMT 
promoter methylation. 
The optimal dosing of TMZ in glioblastoma became a dominant topic in the first 
decade of this century in Neuro-Oncology, in part reflecting the lack of promising 
alternative drugs, in part also reflecting the consideration that TMZ activity is critically 
limited by chemoresistance afforded by MGMT (27, 28). MGMT promoter methylation 
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is observed in 30-40% of glioblastomas, presumably resulting in decreased MGMT 
gene expression in the MGMT promoter-methylated tumor cells, thereby rendering 
glioblastomas more sensitive to TMZ. However, a predictive role of MGMT promoter 
methylation for benefit from alkylating chemotherapy including TMZ has only been 
defined for glioblastoma whereas MGMT promoter methylation is prognostic for 
better outcome with either radiotherapy or chemotherapy in patients with anaplastic 
gliomas (29, 30). This difference in biological significance of MGMT promoter 
methylation is probably not related to grade of malignancy per se, but to the 
differential distribution of isocitrate dehydrogenase (IDH) mutations among these 
tumors. MGMT promoter methylation associated with IDH mutation and the glioma-
associated CpG island methylator phenotype (G-CIMP) does not have the same 
significance as MGMT promoter methylation on the wild-type IDH background of 
glioblastoma (31, 32). 
Since TMZ depletes MGMT protein in peripheral blood mononuclear cells (33) and 
presumably glioblastoma cells, too, it was tempting to speculate that higher doses of 
TMZ given over a longer time frame would eventually deplete MGMT. Accordingly, it 
was assumed that specifically patients with glioblastomas lacking MGMT promoter 
methylation might benefit from dose-intense TMZ regimens. In addition and in 
parallel to DIRECTOR, two further trials explored the potential role of TMZ dose 
intensification in glioblastoma. For the newly diagnosed setting, the hypothesis that 
more TMZ might deplete MGMT and confer a survival benefit was falsified by the 
RTOG 0525 trial which confirmed the strong prognostic role of the MGMT status in 
TMZ-treated patients, but showed no difference between standard-dosed TMZ or a 
three weeks on / one week off regimen for 6-12 cycles in the maintenance phase, 
also not when the analysis was stratified for MGMT status (34). The BR12 trial 
analysed the same two regimens in comparison with procarbacine, CCNU and 
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vincristine (PCV) in recurrent malignant glioma and similarly observed no difference 
between the three arms (35). However, this trial had enrolled chemonaive patients 
with WHO grade III or IV gliomas which does not inform about the current situation in 
clinical practice where recurrent or progressive glioblastoma patients have commonly 
been pretreated with TMZ/RT→TMZ. 
The DIRECTOR trial reports a median TTF in the range of 2 months and yields 
overall no evidence that there are clinically relevant differences between the two 
dosing regimens, regarding either efficacy, safety or tolerability (Figure 2. Tables 2 
and 3). Importantly, the dosing regimens were both confirmed to be feasible, given 
that PD was driving TTF in all, but one patient(s). The PFS-6 rate of 21% is in the 
range of previously reported figures of 11-24% (11, 12, 36). In contrast to the 
RESCUE trial (11), we observed a better PFS in patients off TMZ for 2 months or 
more (Supplementary table 3). Of note, it is uncommon in Europe to give TMZ for 
more than 6 months (Table 1). These considerations indicate that some of the 
patients escalated to dose-intensified TMZ regimens early in the disease course in 
RESCUE as well as in our previous reports (37) were in fact suffering from 
pseudoprogression, artificially raising the PFS-6 rate. Increased awareness of 
pseudoprogression may thus explain an apparent decrease in PFS-6 rates with TMZ 
rechallenge in contemporary studies (12), and challenges all cross trial comparisons 
to older series. Moreover, differences in the PFS-6 figures for TMZ rechallenge – and 
probably CCNU, too - are likely to be related to the proportion of patients with tumors 
with MGMT promoter methylation in these studies, e.g., PFS-6 was 26% with versus 
0% without MGMT promoter methylation in the control arm of the BELOB trial (38). 
The major limitations of the DIRECTOR trial are the relatively small sample size and 
the premature closure of the study which allows for less definitive conclusions. Yet, 
despite the lower than planned sample size and the premature trial closure, the 
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likelyhood of a major difference in efficacy between the different TMZ schedules is 
very low. 
In fact, the most important result of DIRECTOR is the strong prognostic role of the 
MGMT promoter methylation status in patients rechallenged with TMZ that has not 
previously been studied prospectively in an adequately sized patient population. In 
contrast, age and KPS were not prognostic, likely reflecting preselection of patients 
enrolled into randomized trials for recurrent as opposed to newly diagnosed 
glioblastoma enriching patients with a similar, relatively favorable outcome. MGMT 
status was centrally assessed and was available for all patients. Although there was 
only a moderate advantage in median TTF of 3.2 versus 1.8 months in patients with 
MGMT promoter-methylated versus unmethylated tumors, PFS-6 was increased 5.8-
fold, and OS at 12 months 2.4-fold (Figure 2, Table 3). Yet, given the absence of an 
inactive comparator or a placebo, it cannot be excluded that MGMT promoter 
methylation is merely prognostic. Thus, bevacizumab alone was associated with 
superior PFS at 6 months in patients with tumors with versus without MGMT 
promoter methylation in the BELOB trial, too (38), supporting a prognostic role of 
MGMT promoter methylation in recurrent glioblastoma. Randomization between TMZ 
and placebo and the demonstration of benefit from TMZ exclusively in patients with 
tumors with MGMT promoter methylation would be required for definitive 
confirmation, but is neither feasible nor ethical in patients with recurrent glioblastoma.  
The  findings of the DIRECTOR trial have implications for current clinical practice. 
Based on DIRECTOR, TMZ rechallenge should no longer be considered for patients 
with tumors lacking MGMT promoter methylation, but remains a viable option for 
patients with MGMT promoter-methylated glioblastomas, notably after a drug-free 
interval of 2 months or more. Whether TMZ given at 5 out of 28 days would be as 
effective as dose-intense regimens in patients recurring after a drug-free interval, 
 18 
remains uncertain, but the 5/28 regimen may be preferred in that setting because of 
better tolerability. More importantly, it may be speculated that a similarly profound 
prognostic effect of the MGMT status would have been seen, had the patients been 
treated with nitrosoureas instead of TMZ (38). If confirmed, this would call for MGMT 
testing of primary or recurrent tumor and stratification for all, notably smaller 
randomized recurrent glioblastoma trials carrying an alkylator control arm because 
imbalances in the distribution of patients with MGMT-unmethylated versus MGMT-
methylated tumors could severely bias outcome. In conclusion, DIRECTOR supports 
stratified treatment algorithms based on MGMT promoter methylation status in 
recurrent glioblastoma and advocates an alkylator regimen, including dose-dense 
TMZ, as the most appropriate option for patients with glioblastoma harboring MGMT 
promoter methylation. 
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Table 1. Patient characteristics prior to enrolment 
 
 Arm A 
7/7 
N=52 
Arm B 
21/7 
N=53 
Age at diagnosis   
  Median (years) 58 56 
  Range (years) 21-62 37-59 
Gender   
  Male 34 (65%) 35 (66%) 
  Female 18 (35%) 18 (34%) 
MGMT promoter 
  Methylated 
  Unmethylated 
 
28 (53.8%) 
24 (46.2%) 
 
31 (58.5%)  
22 (41.5%) 
First-line therapy   
  TMZ/RT   52 (100.0%)   53 (100.0%) 
  Number of maintenance TMZ cycles   
  No data 1 (1.9%) 0 (0%) 
  <3 9 (17.3%) 12 (22.6%) 
  4-6 32 (61.5%) 33 (62.3%) 
  7 or more 10 (19.2%) 8 (15.1%) 
Time since last TMZ administration 
< 2 months 
> 2 months 
 
20 (38.5%) 
32 (61.5%) 
 
20 (37.7%) 
33 (62.3%) 
Survival 
  Median PFS (months, 95% CI) 
 
12.0 (8.8-17.0) 
 
11.0 (9.2-12.9) 
KPS at study entry   
  90-100 30 (57.7%) 30 (56.6%) 
  70-80 15 (28.8%) 16 (30.2 %) 
  <70 7 (13.5%) 7 (13.2%) 
Steroids at study entry 
  Yes 
  No 
 
16 (30.8%)  
36 (69.2 %) 
 
12 (22.6%) 
41 (77.4%) 
Surgery for recurrence   
  Yes 29 (55.8%) 32 (60.4%) 
  No 23 (44.2%) 21 (39.6%) 
 
Abbreviations: CI, confidence interval; KPS, Karnofsky performance score; MGMT, 
O6-methylguanine DNA methyltransferase; OS, overall survival; PFS, progression-
free survival; TMZ, temozolomide. 
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Table 2. Outcome by treatment arm. 
 
 Arm A (7/14) Arm B (21/28)  
        
 Patients Events Time in months 
(95% CI) 
Patients Events Time in months  
(95% CI) 
p 
Median TTF 52 49 1.8 [1.8; 3.2] 53 49 1.95 [1.84; 3.44] 0.37 
Median survival from 
first study drug 
administration 
52 42 9.8 [6.6; 13.0] 53 45 10.6 [8.1; 11.7] 0.78 
        
   Rate in % 
(95% CI) 
  Rate in % 
(95% CI) 
 
TTF-6 50 42 17.1 [8.2; 28.8] 52 39 25.0 [14.3; 37.3] 0.33 
PFS-6 50 42 17.1 [8.2; 28.8] 52 39 25.0 [14.3; 37.3] 0.33 
Survival rate at 12 
months from first 
study drug 
administration 
45 27 41.0 [26.7; 54.8] 49 33 32.7 [20.2; 45.9] 0.40 
 
Abbreviations: CI, confidence interval; PFS, progression-free survival; TTF, time to treatment failure. 
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Table 3. Outcome by MGMT promoter methylation status. 
 
 MGMT-unmethylated glioblastoma MGMT-methylated glioblastoma  
        
 Patients Events Time in months 
(95% CI) 
Patients Events Time in months 
(95% CI) 
p 
Median TTF 59 56 1.8 [1.8; 2.0] 46 42 3.2 [1.8; 7.3] 0.0014 
Median survival 
from first study 
drug 
administration 
59 50 7.9 [6.3; 10.3] 46 36 12.5 [9.8; 17.4] 0.0009 
        
   Rate in %  
(95% CI) 
  Rate in%  
(95% CI) 
 
PFS-6 58 54 6.9 [2.2; 15.3] 44 27 39.7 [25.5; 53.5] <0.0001 
Survival rate at 
12 months from 
first study drug 
administration 
53 41 22.9 [12.7; 34.9] 41 19 54.1 (37.8; 67.8) 0.0013 
 
Abbreviations: CI, confidence interval; PFS, progression-free survival; TTF, time to treatment failure. 
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Table 4. Multivariate analyses of predictors for inferior TTF. 
 
 Hazard ratio 
and 95% CI 
p 
Arm A versus Arm B 1.16 (0.76-1.76) 0.485 
Age at study entry 50+ versus 18-49 years 1.27 (0.76-2.20) 0.381 
Time interval since last TMZ: < versus > 2 months 1.60 (1.00-2.55) 0.036 
Salvage surgery: no versus yes 1.02 (0.65-1.57) 0.945 
KPS 50-60 versus 90-100 
KPS 70-80 versus 90-100 
1.03 (0.52-1.92) 
1.05 (0.63-1.73) 
0.786 
0.841 
MGMT promoter: unmethylated versus methylated 1.76 (1.11-2.82) 0.017 
 
1Hazard ratios as exponential function of parameter estimates and confidence 
interval. Estimates from a Cox model containing arm, treatment, age, time since last 
TMZ, salvage surgery: no versus yes, KPS, and MGMT promoter methylation status 
as explanatory variables. Other factors which are mentioned in the text, were 
included as additional variables in turn (one at a time). 
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Figure Legends 
 
Figure 1. CONSORT chart. 
 
Figure 2. Clinical outcome. TTF (A) and OS (B) in Arm A (7/14) versus Arm B 
(21/28). TTF (C) and OS (D) in patients without versus with MGMT promoter 
methylation. 
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Supplementary Figure 1. MMSE assessment at study entry, during treatment, 
and at follow-up. Arm a is depicted in green, Arm B in red. 
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 Supplementary Tables 
 
Supplementary Table 1. Safety and tolerability. 
 
 Arm A 
n = 52 
Arm B  
n = 52* 
CTCAE grade 2 3 4 2 3 4 
Hematological toxicity1, n 
Neutropenia 
Lymphopenia 
Thrombocytopenia 
 
0 1 0 0 1 0 
3 8 2 2 14 1 
1 1 1 1 2 0 
Liver enzyme elevation (γ-GT), 
n 
0 0 1 1 0 0 
All infections2, n 5 5 0 5 4 0 
Thrombembolic event, n 4 2 0 1 0 0 
Fatigue, n 4 0 0 4 1 0 
Nausea / Vomiting3, n 6 0 0 4 0 0 
Seizures, n 5 1 0 10 4 0 
Cutaneous adverse events 
(dermatitis, allergic rash, 
alopecia), n 
3 0 0 1 0 0 
 
*1 patient in Arm B did not receive any study drug. 
1 The criteria were solely based on hematological toxicities that were observed while the 
patients were on treatment. To continue TMZ after a drug-free week, the following conditions 
had to be met: Absolute neutrophil count [counts/µl] (ANC) ≥ 1.5 x 103, Lymphocytes 
[counts/µl] (L) ≥ 500, Platelets [counts/µl] (P) ≥ 1 x 105, Hb [g/dl] ≥ 9. Dose adjustments were 
performed in dose levels. A dose level was defined as a step of 30 mg/m2 in Arm A and as a 
step of 20 mg/m2 in Arm B. Patients in Arm A started with a initial dose of 120 mg/m2. 
Patients in Arm B started with an initial dose of 80 mg/m2. If the following conditions were 
met throughout the first cycle, the dose was escalated in each arm as follows: ANC ≥ 2 x 103, 
L ≥ 800, P ≥ 1 x 105, Hb ≥ 11 [g/dl]; Dosage  for second cycle Arm A: 150 mg/m2, Arm B: 100 
mg/m2. Further dose escalations beyond 150 mg/m2 in Arm A and beyond 100 mg/m2 in Arm 
B were not allowed. TMZ administration should be interrupted if any of the following toxicities 
occured during a treatment week: ANC < 1.0 x 103, L ≥ 250, P < 5 x 104. TMZ administration 
should also be interrupted if non-haematological toxicities of CTC grade IV occur or if non-
haematological toxicities of CTC grade III persist longer than 14 days. The occurrence of two 
of the following toxicities in line I or one the following toxicities in line II either in a treatment 
week or in a drug-free week necessitated a dose reduction in the following cycle: Line I 
(Reduction of dose levels -1) 1.0 x 103 < ANC < 1.5 x 103, 400 < L < 500, P 4 x 104 < P < 8 x 
104; Line II (Reduction of dose levels -2) 0.5 x 103 < ANC < 1.0 x 103, 250< L < 400, 1x104 < 
 P <4x104. Treatment could be withheld up to 8 weeks after the last intake of TMZ. 
Interruption for more than 8 weeks due to hematologic toxicity was defined as treatment 
failure because of hematological toxicity, leading to withdrawal of the patient from study 
treatment. 
2 If toxicities occurred (as outlined above), prophylactic treatment with aciclovir as well as 
trimethoprim and sulfamethoxazol should be started depending on the lymphocyte counts 
and concomitant steroid medication: Lymphocytes [counts/µl] (L) < 500 / µl, concomitant 
steroid medication: Aciclovir 5mg/kg t.i.d.,  Sulfamethoxazol 800 mg & Trimethoprim 160 mg 
b.i.d. once a week; L < 500 / µl, no concomitant steroid medication: Sulfamethoxazol 800 mg 
& Trimethoprim 160 mg b.i.d. once a week; L > 500/µl, concomitant steroid medication: 
Sulfamethoxazol 800 mg & Trimethoprim 160 mg: b.i.d. once a week; L > 500/µl, no 
concomitant steroid medication: Optional. 
3 Antiemetics were applied to prevent nausea and vomiting during study treatment. The 
following drugs were recommended: ondansetron 4 mg, tropisetron 5 mg, 20 drops 
metoclopramide, domperidon 10 mg. 
 
 
 
 Supplementary Table 2. Outcome by MGMT promoter methylation status and treatment arm. 
 
 MGMT-unmethylated glioblastoma MGMT-methylated glioblastoma  
        
Arm A Patients Events Time in months (95% CI) Patients Events Time in months (95% CI) p 
Median TTF 28 27 1.8 [1.6; 2.9] 24 22 1.9 [1.7; 5.7] 0.164 
Median 
survival from 
first study drug 
administration 
28 25 6.6 [5.1; 11.5] 24 17 13.0 [9.3-17.9] 0.040 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 28 26 7 [1; 20] 22 16 29 [13; 49] 0.041 
Survival rate at 
12 months 
from first study 
drug 
administration 
26 19 27 [12; 45] 19 8 59 [34; 77] 0.064 
        
Arm B Patients Events Time in months (95% CI) Patients Events Time in months 
(95% CI) 
p 
Median TTF 31 29 1.9 [1.8; 1.9] 22 20 6.3 [2.0; 9.3] 0.0015 
Median 
survival from 
first study drug 
administration 
31 26 8.1 [6.1; 10.9] 22 19 12.1 [9.4; 21.5] 0.0065 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 30 28 7 [1; 19] 22 11 50 [28; 68] 0.0003 
Survival rate at 27 22 19 [7; 35] 22 11 50 [28; 68] 0.016 
 12 months 
from first study 
drug 
administration 
 
Abbreviations: CI, confidence interval; PFS, progression-free survival; TTF, time to treatment failure.
 
 
 
Supplementary Table 3. Outcome by interval from last TMZ administration and MGMT promoter methylation status. 
 
 Last TMZ < 2 months Last TMZ > 2 months  
        
All patients Patients Events Time in months (95% CI) Patients Events Time in months (95% CI) p 
Median TTF 40 39 1.8 [1.7; 2.0] 65 59 2.0 [1.8; 3.8] 0.0013 
Median 
survival from 
first study 
drug 
administration 
40 34 9.3 [7.3; 11.6] 65 53 10.7 [7.9; 12.5] 0.032 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 39 34 13 [5; 25] 63 47 26 [16; 37] 0.079 
Survival rate 
at 12 months 
from first 
study drug 
administration 
34 25 27 [14; 43] 60 35 42 [29; 54] 0.137 
        
Arm A Patients Events Median time, months (95% CI) Patients Events Median time, months (95% CI) p 
Median TTF 20 20 1.8 [1.5; 2.3] 32 29 2.0 [1.8; 4.2] 0.024 
Median 
survival from 
first study 
drug 
administration 
20 17 8.5 [3.2; 12.0] 32 25 12.1 [6.4; 16.1] 0.074 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 20 18 10 [2; 27] 30 24 22 [9; 38] 0.253 
 
  
 
 
 
Survival rate 
at 12 months 
from first 
study drug 
administration 
17 13 25 [8; 46] 28 14 50 [31; 67] 0.069 
        
Arm B Patients Events Median time, months (95% CI) Patients Events Median time, months (95% CI) p 
Median TTF 20 19 1.9 [1.8; 2.6] 33 30 2.0 [1.8; 5.5] 0.04 
Median 
survival from 
first study 
drug 
administration 
20 17 11.5 [5.7; 13.7] 33 28 10.6 [6.9; 12.6] 0.25 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 19 16 16 [4; 35] 33 23 30 [16; 46] 0.21 
Survival rate 
at 12 months 
from first 
study drug 
administration 
17 12 30 [11; 51] 32 21 34 [19; 51] 0.72 
 Last TMZ < 2 months Last TMZ > 2 months  
        
MGMT 
promoter 
unmethylated 
Patients Events Time in months (95% CI) Patients Events Time in months (95% CI) p 
Median TTF 29 28 1.9 (1.8; 2.0) 30 28 1.8 (1.8; 3.7) 0.30 
Median 
survival from 
first study 
29 25 8.5 [5.7; 12.0] 30 26 6.9 [5.6; 10.3] 0.76 
 
  
 
 
 
drug 
administration 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 28 26 7 [1; 20] 30 28 7 [1; 19] 0.47 
Survival rate 
at 12 months 
from first 
study drug 
administration 
25 18 28 [13; 46]  28 23 18 [7; 34] 0.19 
        
Arm A Patients Events Median time, months (95% CI) Patients Events Median time, months (95% CI) p 
Median TTF 13 13 1.8 [1.5; 3.3] 15 14 1.8 [1.0; 3.7] 0.55 
Median 
survival from 
first study 
drug 
administration 
13 12 8.5 [2.9; 12.6] 15 13 6.4 [5.1; 12.1] 0.92 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 13 12 8 [0.5; 29] 15 14 7 [0.4; 26] 0.46 
Survival rate 
at 12 months 
from first 
study drug 
administration 
12 9 25 [6; 51] 14 10 29 [9; 53]  0.42 
        
Arm B Patients Events Median time, months (95% CI) Patients Events Median time, months (95% CI) p 
Median TTF 16 15 1.9 [1.6; 1.9] 15 14 1.8 [1.7; 3.7] 0.53 
Median 16 13 9.1 [4.1; 13.7] 15 13 8.0 [3.8; 10.6] 0.42 
 
  
 
 
 
survival from 
first study 
drug 
administration 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 15 14 7 [0.4; 26]  15 14 6.7 [0.4; 26] 1.00 
Survival rate 
at 12 months 
from first 
study drug 
administration 
13 9 31 [10; 56]  14 13 7 [0.5; 28] 0.05 
 Last TMZ < 2 months Last TMZ > 2 months  
        
MGMT 
promoter 
methylated 
Patients Events Time in months (95% CI) Patients Events Time in months (95% CI) p 
Median TTF 11 11 1.8 (1.4; 7.3) 35 31 5.5 (2.0; 9.3) 0.01 
Median 
survival from 
first study 
drug 
administration 
11 9 11.3 (3.1; 13.0) 35 27 16.1 (9.8; 21.5) 0.02 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 11 8 27 [7; 54] 33 19 44 [27; 59] 0.15 
Survival rate 
at 12 months 
from first 
study drug 
administration 
9 7 23 [3; 52] 32 12 63 [44; 77] 0.01 
 
  
 
 
 
        
Arm A Patients Events Median time, months (95% CI) Patients Events Median time, months (95% CI) p 
Median TTF 7 7 1.7 [1.2; 1.8] 17 15 5.5 [1.8; 9.7] 0.01 
Median 
survival from 
first study 
drug 
administration 
7 5 9.3 [3.1; 13.0] 17 12 16.1 [6.8; 19.0] 0.03 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 7 6 14 [0.6; 46] 15 10 36 [14; 59]  0.12 
Survival rate 
at 12 months 
from first 
study drug 
administration 
5 4 21 [1; 60] 14 4 72 [42; 89] 0.01 
        
Arm B Patients Events Median time, months (95% CI) Patients Events Median time, months (95% CI) p 
Median TTF 4 4 5.5 [1.8; 9.2] 18 16 6.3 [2.0; 9.9] 0.37 
Median 
survival from 
first study 
drug 
administration 
4 4 11.5 [9.4; 17.4] 18 15 14.5 [9.0; 21.8] 0.26 
        
   Rate in % (95% CI)   Rate in % (95% CI)  
PFS-6 4 2 50 [6; 84] 18 9 50 [26; 70] 1.00 
Survival rate 
at 12 months 
from first 
4 3 25 [0.8; 67] 18 8 56 [31; 75] 0.11 
 
  
 
 
 
study drug 
administration 
 
 
Abbreviations: CI, confidence interval; PFS, progression-free survival; TMZ, temozolomide; TTF, time to treatment failure.  
 
  
 
 
 
Supplementary Table 4. Adherence to Mini Mental Status data collection over 
the course of the study.1 
 Visit 
done 
Patients with test: n / % 
DONE NOT DONE MISSING 
Test Visit Visit 
Cycle 
105 100 95.24 5 4.76 . . 
Mini Mental 
Status 
Baseline 
visit 
 
1 
Treatment 
phase  
- Every 4 
weeks 
1 94 85 90.43 9 9.57 . . 
2 73 60 82.19 12 16.44 1 1.37 
3 33 29 87.88 4 12.12 . . 
4 31 30 96.77 1 3.23 . . 
5 21 21 100.00 . . . . 
6 20 18 90.00 2 10.00 . . 
7 16 16 100.00 . . . . 
8 14 13 92.86 1 7.14 . . 
9 11 11 100.00 . . . . 
10 9 9 100.00 . . . . 
11 7 6 85.71 1 14.29 . . 
12 6 6 100.00 . . . . 
13 2 2 100.00 . . . . 
14 1 1 100.00 . . . . 
15 1 1 100.00 . . . . 
16 1 1 100.00 . . . . 
17 1 1 100.00 . . . . 
18 1 1 100.00 . . . . 
19 1 1 100.00 . . . . 
20 1 1 100.00 . . . . 
End of study 
medication 
visit 1 102 67 65.69 28 27.45 7 6.86 
Follow-up 
visit (after 
treatment 
failure), 
1 55 31 56.36 23 41.82 1 1.82 
2 41 27 65.85 13 31.71 1 2.44 
3 26 20 76.92 6 23.08 . . 
 
  
 
 
 
 Visit 
done 
Patients with test: n / % 
DONE NOT DONE MISSING 
thereafter in 
8-weekly 
intervals 
4 20 13 65.00 7 35.00 . . 
5 12 8 66.67 4 33.33 . . 
6 7 5 71.43 2 28.57 . . 
7 3 3 100.00 . . . . 
8 3 2 66.67 1 33.33 . . 
9 1 . . 1 100.00 . . 
 
 
 
 
  
 
 
 
Supplementary Table 5. Treatment effect (Arm B versus Arm A) on EORTC-
QLQ-C30 and –BN20 scales evaluated at timepoint 90 days1. 
Questionnaire Scale Effect 95% CI p value 
EORTC QLQ-C30 Appetite loss -5.08 [-14.87;   4.71] 0.3082 
 Cognitive functioning -1.91 [-12.18;   8.36] 0.7142 
 Constipation -0.58 [-11.04;   9.89] 0.9135 
 Dyspnoea -1.46 [-10.48;   7.56] 0.7501 
 Emotional functioning -4.11 [-12.87;   4.65] 0.3568 
 Fatigue -4.55 [-14.21;   5.10] 0.3536 
 Financial difficulties -5.82 [-14.82;   3.18] 0.2038 
 Global health status 0.02 [ -8.38;   8.43] 0.9954 
 Insomnia -3.39 [-12.83;   6.06] 0.4811 
 Nausea and vomiting 2.47 [ -3.99;   8.94] 0.4522 
 Pain 4.36 [ -5.90;  14.62] 0.4036 
 Physical functioning -4.73 [-13.79;   4.32] 0.3044 
 Role functioning -1.26 [-13.58;  11.05] 0.8400 
 Social functioning -2.16 [-11.55;   7.23] 0.6504 
EORTC QLQ-BN20 Bladder control 1.72 [ -9.96;  13.40] 0.7717 
 Communication deficit 1.42 [ -9.70;  12.55] 0.8014 
 Drowsiness -6.79 [-16.17;   2.60] 0.1555 
 Future uncertainty -7.24 [-16.72;   2.23] 0.1335 
 Hair loss -0.58 [ -9.06;   7.90] 0.8928 
 Headaches 11.83 [  1.48;  22.18] 0.0253 
 Itchy skin 0.20 [ -8.01;   8.40] 0.9626 
 Motor dysfunction -3.37 [-13.81;   7.07] 0.5255 
 Seizures 6.04 [ -3.15;  15.22] 0.1969 
 Visual disorder 5.24 [ -1.77;  12.24] 0.1423 
1Estimates of expected values of treatment differences at timepoint 90 days, obtained 
from a generalized linear mixed model incorporating baseline score, treatment group, 
days after randomization with time/treatment and time/baseline interactions. 
 
  
 
  
 
 
 
Supplementary Table 6. Absolute changes of (0-100) score points of quality of 
life (as assessed by the EORTC-QLQ-C30 and -BN20 scales) within one 
treatment cycle of 28 days in Arms A and B, along with local p-values for 
difference in slopes.1  
Questionnaire Scale Arm A Arm B p value 
EORTC QLQ-
C30 
Appetite loss 0.130 0.821 0.054 
 Cognitive functioning 0.270 0.984 0.055 
 Constipation -1.02 -.396 0.110 
 Dyspnoea 0.093 0.422 0.316 
 Emotional functioning 0.149 0.731 0.040 
 Fatigue 0.124 1.118 0.005 
 Financial difficulties -.021 -.201 0.586 
 Global health status 0.362 0.301 0.832 
 Insomnia 0.156 0.362 0.647 
 Nausea and vomiting 0.006 -.198 0.382 
 Pain -.364 0.795 0.001 
 Physical functioning 0.310 1.142 0.007 
 Role functioning 0.321 0.830 0.159 
 Social functioning 0.660 1.167 0.119 
EORTC QLQ-
BN20 
Bladder control 0.141 0.655 0.133 
 Communication deficit -.050 0.886 0.017 
 Drowsiness 0.494 1.119 0.116 
 Future uncertainty 0.300 1.199 0.003 
 Hair loss 0.009 0.296 0.362 
 Headaches -.099 0.693 0.039 
 Itchy skin 0.147 -.058 0.566 
 Motor dysfunction 0.519 0.872 0.260 
 Seizures 0.057 0.324 0.447 
 Visual disorder -.019 0.580 0.037 
1Estimates of treatment by time interaction parameters in generalized linear mixed 
model incorporating baseline score, treatment group, days after randomization with 
time/treatment and time/baseline interactions. 
  
 
  
 
 
 
Supplementary Table 7. Adherence to EORTC-QLQ-BN20 and –C30 data 
collection over the course of the study.1  
 
 Visit 
done 
Patients with test: n / % 
DONE NOT 
DONE 
MISSING 
Test Visit Visit 
Cycle 
105 101 96.19 3 2.86 1 0.95 
EORTC QLQ-
C30/-BN20 
Baseline 
visit 
1 
Treatment 
phase – 
every 8 
weeks 
1 86 75 87.21 7 8.14 4 4.65 
2 38 34 89.47 2 5.26 2 5.26 
3 23 21 91.30 1 4.35 1 4.35 
4 14 14 100.00 . . . . 
5 11 11 100.00 . . . . 
6 6 6 100.00 . . . . 
7 1 1 100.00 . . . . 
8 1 1 100.00 . . . . 
9 1 1 100.00 . . . . 
10 1 1 100.00 . . . . 
End of 
study 
medication 
visit 
1 102 66 64.71 26 25.49 10 9.80 
Follow-up 
visit (after 
treatment 
failure), 
thereafter 
in 8-weekly 
intervals 
1 55 36 65.45 18 32.73 1 1.82 
2 41 30 73.17 11 26.83 . . 
3 26 21 80.77 5 19.23 . . 
4 20 17 85.00 3 15.00 . . 
5 12 9 75.00 3 25.00 . . 
6 7 5 71.43 2 28.57 . . 
7 3 3 100.00 . . . . 
8 3 3 100.00 . . . . 
9 1 1 100.00 . . . . 
 
 
  


